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Abstract As a lot of reviews are available on Zika virus
(ZIKV), in this short commentary, we will focus on the recent
advances and gaps in knowledge regarding our understanding
of ZIKV infections and on the reaction to the “ZIKV crisis.”
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Recent Advances and Gaps in Knowledge
Over the 60 years following ZIKV discovery and prior to the
ZIKVoutbreak on the Yap Island in 2007, less than 20 human
ZIKV infections had been confirmed. The first severe neuro-
logic complications associated with ZIKV infection (Guillain-
Barré syndrome (GBS)) and the potential for materno-fetal,
sexual, and post-transfusion transmission were first described
during the 2013–2014 French Polynesian outbreak. Even
though they were published in high impact factor reviews,
data from French Polynesia were not really taken into consid-
eration. The emergence of ZIKV in the Americas in 2015 was
associated with a dramatic increase in incidence of microceph-
aly. As of August 2016, ZIKV is continuing its spread in the
Americas with the first autochthonous infections reported in
the contiguous continental US in Florida. While ZIKV is still
circulating in the Pacific, ZIKV outbreaks were recently re-
ported in Africa and Southeast Asia. There is a high potential
for ZIKV to spread in sub-Saharan Africa and Southeast Asia
as well as on the Indian Ocean Islands.
Nevertheless, the real burden of ZIKV is unknown. In
the past, ZIKV infections have been underreported be-
cause infections were misdiagnosed and thought to be
caused by other related arboviruses such as dengue virus
(DENV) and laboratory diagnostic tools were lacking. In
countries like Vietnam, Thailand, Maldives, and Vanuatu,
ZIKV circulation has been confirmed only by the detec-
tion of imported cases (travelers returning from the area
and developing symptoms were further investigated and
diagnosed as ZIKV related) proving that ZIKV was circu-
lating in these regions but was undetected. On the other
hand, the number of infections actually reported relies
only on estimates and suspected cases, over or under es-
timating the number of infections.
ZIKV, like DENV, adapted from feral mosquitoes and
monkeys in a sylvatic zoonotic transmission cycle to
Aedes aegypti and Aedes albopictus as vectors, and to
humans as reservoir in an urban transmission cycle, mak-
ing the 2.2 billion people leaving in ZIKV-compatible
environment at risk for ZIKV infection. To date, ZIKV
does not seem to have adapted to Culex sp. mosquitoes
and therefore the main vector for West Nile virus (WNV)
is not a competent vector for ZIKV. Recent findings sup-
port vertical transmission of ZIKV in Ae. aegypti, as dem-
onstrated in the past for DENV and yellow fever virus
(YFV), providing a mechanism for persistence during ad-
verse climatic conditions or in the absence of susceptible
vertebrate hosts. New mosquito vector control strategies
such as release of Wolbachia infected, genetically modi-
fied or irradiated mosquitoes are promising, but large
scale implementation remains challenging.
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Sexual transmission from man to woman, man to man,
and recently woman to man has been reported. The im-
pact of ZIKV sexual transmission in active ZIKV areas is
impossible to evaluate because all the population is also
exposed to mosquito bites. The maximum duration of in-
fectivity in semen is unknown.
If the link between ZIKV and microcephaly is
established, the number of microcephaly cases related to
ZIKV is unknown because all reported cases are not con-
firmed and all etiologies of microcephaly are not investi-
gated. For example, as of June 2016, Brazil reported 8165
cases of microcephaly and other central nervous system
abnormalities; of these, 1638 were confirmed cases of
microcephaly including 270 laboratory confirmed cases
of ZIKV-related microcephaly. In vitro studies using neu-
ral progenitor cells and animal models have demonstrated
the neurotropism of ZIKV.
Gaps on materno-fetal complications of ZIKV have
been recently reviewed in the Lancet: “We know that a
pregnant woman infected with ZIKV runs a risk of having
a microcephalic baby but we can’t tell her how high that
risk is and how it might evolve over the course of her
pregnancy. We don’t know what is the full spectrum of
the ZIKV-caused congenital defects. Will apparently un-
affected children whose mothers had ZIKV in pregnancy
develop normally? Will they be able to walk and talk
normally? Will they be mentally impaired or have other
problems that only become evident years later?”
Within the Flavivirus genus, there is an immunity against
homologous flaviviruses. Immunity against DENV is not pro-
tective against ZIKV, as demonstrated by the emergence of
ZIKV in high endemic areas for DENV. On the contrary,
in vitro studies suggest that previous immunity to DENV
may increase the risk for severe ZIKV infection but this needs
further investigation in large longitudinal human cohorts. The
duration of immunity against ZIKV is unknown.
The two main ZIKV lineages are African and Asian. To
date, all complications are associated with the Asian lin-
eage and, within the Asian lineage, only since ZIKV
emerged in French Polynesia (no complication described
during the first ZIKV outbreak in Yap, 2007, also causes
by the Asian lineage). In vitro studies suggest a cross-
protection against ZIKV Asian lineage by antibodies
against ZIKV African lineage.
The main favorable predisposing factor of ZIKV emer-
gence is probably its adaptation to new mosquito vectors.
Mutations associated with increased virulence have been
described for other arboviruses such as CHIKV and WNV,
even if genetic changes are detected in the currently cir-
culating strains of ZIKV, the correlation between muta-
tions and increased virulence has not been demonstrated.
Other favorable factors for emergence are increased ur-
banization, tourism industry, and travel exchanges as well
as lack of effective mosquito control and viral introduc-
tion in areas lacking herd immunity against ZIKV.
Diagnosis of ZIKV infections relies on molecular diag-
nosis and/or seroneutralization tests which can only be
performed by specialized laboratories and with no rapid
test currently available, ZIKV diagnosis is a challenge in
resource limited countries.
Reacting to the ZIKV Crisis
ZIKV emergence is dramatic for many countries and pre-
ventive measures are needed in active ZIKV transmission
areas; however, in areas lacking ZIKV competent mosqui-
to vectors, the risk for ZIKV emergence is minimal and
ZIKV-related concerns should be limited to pregnant
women who might have contracted the infection during
travels to active ZIKV transmission areas or have been
contaminated by infected partners.
Sexual transmission of ZIKV is in the spotlight but it
should be kept in mind that ZIKV is principally a mosquito-
borne pathogen. Even if ZIKV can be transmitted by sexual
intercourse, it is far from being the most dangerous sexual
transmitted pathogen.
Recently, ZIKV emerged on the continental US in the
state of Florida and few cases of ZIKV transmission by
blood transfusion have been reported in Brazil. Health
authorities requested countrywide implementation of
ZIKV nucleic acid testing (NAT) for the screening of all
individual blood donations in the USA, even in states
without competent mosquito vectors. On the other hand,
in several African countries, only insensitive rapid tests
are performed to screen blood donors for HIV. Pathogen
inactivation of blood products, when possible, could rep-
resent an interesting alternative to NAT blood screening,
especially in at-risk areas where mosquito vectors are
present and for blood components to be transfused to high
risk recipients (pregnant women).
Another exaggerated reaction was the recommendation
to cancel the Olympic Games in Brazil while the local en-
tomologists and infectiologists agreed that in August, the
risk for ZIKV transmission would be low in Brazil. Indeed,
in Brazil, the arbovirus season is from January to April. In
addition, the Olympic games attracted a limited number of
foreigners outside of the participating athletes and the ac-
companying staff and represent a minor population com-
pared to the daily flow of international travelers making
the trip for professional or touristic reasons.
Another questionable move was that because of lack of
funds dedicated to ZIKV, the redirection of funds that
were allocated to other causes such as Ebola, Malaria,
YFV to support urgently needed research. A tribune has
been published in Nature in September 2016 entitled “the
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US government should not redirect vital funds to work on
ZIKV at the expense of other health priorities,” like yel-
low fever or malaria that threaten Latin America and
Africa. Indeed, there is an urgent need to fill in the gap
of knowledge to inform adequate reaction to ZIKV but
one needs to keep in mind that humanity is under constant
threat and the risk for other infectious agents to emerge
and become the next most frightening agent is high.
Therefore, instead of redirecting funds attributed to im-
portant research, additional funding should be released
to face the threat posed by ZIKV.
Conclusion
Since its emergence in the USA, ZIKV has captured the at-
tention from the international community for the past year.
The future of ZIKV is unpredictable but the story of ZIKV is
certainly not finished. Nevertheless, other pathogens like ma-
laria, HIV, and Ebola should not be neglected, and efforts for
other arboviruses such as DENV which is a concern for bil-
lions of children and adults throughout the tropics and YFV
for which a vaccine is available should continue.
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